




Clinical Research Study for Patients with Hepatocellular Carcinoma



Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.



Who Can Participate:

- 18 years of age or older
- Diagnosed with advanced HCC
- Not pregnant or breastfeeding

Study Design:

- Physical exam and medical history
- Imaging, such as CT or MRI scan
- Electrocardiogram (EKG)
- Patients will receive the study medications every 2- 4 weeks

For More Information
Office of Patient Recruitment

800-411-1222

prpl@cc.nih.gov

Online: <https://go.usa.gov/xpeBG>

Refer to study #19-C-0094



NIH.... Turning Discovery Into Health®

NIH Clinical Center
America's Research Hospital
located in Bethesda, MD
Metro Redline (Medical Center stop)